Want to see CH:IDIA full AI Analyst Report?
IDIA Stock Chart & Stats
CHF5.34
CHF0.49(7.95%)
At close: 4:00 PM EDT
CHF5.34
CHF0.49(7.95%)
Day’s Range― - ―
52-Week RangeCHF2.80 - CHF7.56
Previous CloseN/A
Volume1.17M
Average Volume (3M)1.12M
Market Cap
CHF1.14B
Enterprise ValueCHF3.01B
Total Cash (Recent Filing)CHF88.69M
Total Debt (Recent Filing)CHF1.32B
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Oct 29, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend Yield86.75%
Share Statistics
EPS (TTM)-1.31
Shares Outstanding269,779,600
10 Day Avg. Volume902,551
30 Day Avg. Volume1,122,015
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-0.80
Price to Sales (P/S)4.14
P/FCF Ratio-5.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF5.75Price Target Upside7.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)CHF226.18M
Bulls Say, Bears Say
Bulls Say
Proprietary Drug PipelineIdorsia’s proprietary small-molecule pipeline gives it potential control over product development and commercialization across several therapeutic areas. This model can support differentiated medicines and future recurring revenue if candidates achieve approval and market adoption.
Partnership And Royalty ModelPartnerships with larger pharmaceutical companies can broaden development and commercialization capacity while generating milestone and royalty income. This structure may reduce the need for Idorsia to fund every program alone and provides multiple potential revenue streams.
Strong Gross MarginAn approximately 81% gross margin indicates that Idorsia’s products and related revenue have meaningful economic value before operating expenses. If revenue stabilizes and development costs become more disciplined, this gross-profit profile could support future operating leverage.
Bears Say
Deep Operating LossesFalling revenue combined with EBIT, EBITDA and net margins near -99%, -91% and -158% shows that current operations are not covering the company’s cost base. Persistent losses weaken internal funding capacity and make a durable return to profitability uncertain.
Ongoing Cash ConsumptionNegative operating and free cash flow demonstrate that Idorsia continues to consume cash to sustain its business and development activities. Further deterioration would increase reliance on external financing, potentially limiting investment flexibility and pressuring strategic choices.
Highly Stressed Balance SheetMaterially negative equity and debt that is large relative to the asset base create a highly constrained financial position. This reduces resilience during continued losses, raises funding and refinancing pressure, and limits the company’s ability to absorb setbacks.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF2.79 and its highest was CHF7.56 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF1.14B.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 6 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Jul 30, 2026. The company reported -CHF0.17 earnings per share for the quarter, beating the consensus estimate of -CHF0.195 by CHF0.025.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of 86.75%. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.19.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 269,779,600 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.17 in its last earnings report, beating expectations of -CHF0.195. Following the earnings report the stock price went down -4.962%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis. It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury. The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod. Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF5.75
▲(7.68% Upside)
Technical Analysis
Addex Therapeutics
―
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―